Results 201 to 210 of about 714,773 (317)
Advanced Science, EarlyView.LNPsD18, a cationic liposome that enhances antigen‐presenting cell uptake in the spleen and tumor without targeting ligands is developed. Co‐delivering neoantigens and a TLR9 agonist significantly improve DC activation, tumor immunity, and survival in liver and colorectal cancer models, demonstrating the importance of dual‐site APC targeting for cancer
Yu Xu +12 more
wiley +1 more source
Hepatitis B virus infection after immunization: How serious it is? An updated review. [PDF]
Clin Exp MedMarjani A +6 more
europepmc +1 more source
A METHOD OF ESTIMATING THE STRENGTH OF A VACCINE BY A STANDARD BACTERIAL EMULSION [PDF]
, 1912 John Hicks
openalex +1 more source
Advanced Science, EarlyView.This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang +5 more
wiley +1 more source
Financing the introduction of new vaccines to the national immunisation programme in China: challenges and options for action. [PDF]
BMJ Glob HealthZhang X, Chen S, Zhu K, Tang S.
europepmc +1 more source
AN UNUSUAL CASE OF APPENDIX ABSCESS DUE TO THE PNEUMOCOCCUS AND BACILLUS COLI COMMUNIS: TREATMENT BY DOUBLE VACCINE: RECOVERY [PDF]
, 1909 Edward F. Harrison
openalex +1 more source
Advanced Science, EarlyView.Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin +3 more
wiley +1 more source
COVID‐19 in the Pacific territories: Isolation, borders and the complexities of governance
Asia &the Pacific Policy Studies, Volume 9, Issue 3, Page 394-407, September 2022., 2022 Abstract Early experience of COVID‐19 in seven Pacific politically dependent territories (Guam, American Samoa, Pitcairn, Tokelau, French Polynesia, Wallis and Futuna, and New Caledonia) emphasises a diversity of contexts, responses, outcomes and possible futures.
John Connell
wiley +1 more source
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Advanced Science, EarlyView.STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken +3 more
wiley +1 more source
BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry
Archiv der Pharmazie, Volume 356, Issue 1, January 2023., 2023 Drug repurposing has the potential to accelerate the discovery of TMPRSS2 inhibitors acting as COVID‐19 antivirals. In this regard, a low throughput screening led to the identification of BC‐11 as a covalent TMPRSS2 fragment inhibitor (IC50 = 1.44 µM), displaying significant SARS‐CoV‐2 entry inhibition (EC50 = 66 µM). Abstract Host cell entry of severe
Aurélien F. A. Moumbock +3 more
wiley +1 more source